Report from the American Society of Clinical Oncology (ASCO), Chicago IL, May 29-June 2, 2015 – Bosulif (bosutinib) is one of the more recent TKIs used for the treatment of CML. It’s a potent drug that is generally kept in reserve for people with an inadequate response or poor t
Report from the American Society of Clinical Oncology (ASCO), Chicago IL, May 29-June 2, 2015 – Tyrosine kinase inhibitors (TKIs) have changed the face of treatment, transforming CML into a manageable illness where once it was deadly. But two studies presented at ASCO 2015 sugge
When starting treatment with a TKI, achieving an early response to medication bodes well for future success. If a medication can suppress leukemia cells quickly, it’s less likely that other mutations will emerge.
Part 1 When a person first starts treatment for CML, an obvious concern is whether the medication will work. Will CML respond, or is your body somehow resistant to the TKI (tyrosine kinase inhibitor)? But what does “treatment resistance” mean, and what can be done about it?
CML-IQ is pleased to announce CML radio – featuring news, views and insights about chronic myelogenous leukemia. In part 2, our panel of CML nurses address common questions people have after living with CML for a few years.